N. Scott Fine
Chairman of the Board and Chief Executive Officer
Mr. Fine is the Chief Executive Officer and Chairman of CTD Holdings Inc., a biotechnology company focused on developing novel therapeutics based on cyclodextrin technologies. Additionally, Mr. Fine is a member of the Board of Directors of Kenon Holdings Ltd., as well as Lead Director for Forward Industries, and Sole Director of Operational Technology Stichting. He also serves as Vice Chairman of the Board for Pacific Drilling.
Mr. Fine has been involved in Investment Banking for over 35 years working on a multitude of debt and equity financings, buy and sell side M & A, strategic advisory work and corporate restructurings. Much of his time has been focused on transactions in the healthcare and consumer products area, including time with The Tempo Group of Jakarta, Indonesia when Mr. Fine and his family resided in Jakarta.
Mr. Fine was the lead investment banker on the Initial Public Offering of Keurig Green Mountain Coffee Roasters and Central European Distribution Corporation, a multi-billion-dollar alcohol company. He was also involved in an Equity Strategic Alliance between Research Medical and the Tempo Group.
Mr. Fine continued his involvement with CEDC serving as a director from 1996 until 2014, during which time he led the CEDC Board's successful efforts in 2013 to restructure the company through a pre-packaged Chapter 11 process whereby CEDC was acquired by the Russian Standard alcohol group.
He also served as Sole Director of Better Place Inc. from 2013 until 2015. In his role, there Mr. Fine successfully managed the global wind down of the Company in a timely and efficient manner which was approved by both the Delaware and Israeli Courts.
Mr. Fine devotes time to several non-profit organizations, including through his service on the Board of Trustees for the IWM American Air Museum in Britain.
Mr. Fine has been a guest lecturer at Ohio State University's Moritz School of Law.
Dr. Sharon H. Hrynkow
Senior Vice President of Medical Affairs
Dr. Hrynkow was appointed by the Board of Directors in this role in September 2015 to lead the company's clinical and scientific program. Her leadership roles over the past twenty years include service as a Senior Executive at the National Institutes of Health (NIH), where she was the Deputy Director and Acting Director of the Fogarty International Center, the focal point for international research and training and for diplomatic relations for the NIH. Dr. Hrynkow also served as Associate Director of the National Institute on Environmental Health Sciences and Senior Advisor to the NIH Deputy Director. Since 2012, Dr. Hrynkow has been the President of the Global Virus Network, a non-profit organization working to combat pandemic viral disease.
A developmental neuroscientist by training, Dr. Hrynkow has worked passionately to advance science for the benefit of society. She serves on many advisory committees for national and international organizations, and has been recognized for her contributions to global health and global science by scientific and political leaders and organizations, including with the US President's Merit Award for Senior Executives, the Order of Merit from the King of Norway and elected Fellow of the American Association for the Advancement of Science. She is an elected member of the Council on Foreign Relations.
Dr. Jeffrey L. Tate
Director, Chief Operating Officer and Chief Scientific Officer
Dr. Tate is a seasoned executive with more than 30 years of experience in the biotechnology, pharmaceutical and nutritional supplements industries including: branded generic drugs, intellectual property strategy, product development, and cGMP manufacturing. He is intimately familiar with food and drug marketing approval procedures, documentation and strategy in U.S. and foreign markets, experienced in implementation of all aspects of regulatory compliance and in successfully communicating with regulatory agency representatives.
Dr. Tate has successfully established integrated regulatory compliance programs resulting in timely, cost effective corporate-wide compliance, meeting regulatory agency requirements and customer expectations. He closely monitors developments in U.S. and international regulations to maintain compliance and identify regulatory and intellectual property strategies for new products and markets. He holds patents and trademarks in material processing and food formulation.